Choosing Second-Line Therapy for HCC After Atezolizumab/Bevacizumab
Daneng Li, MD, discusses potential second-line options following treatment with bevacizumab plus atezolizumab in patients with hepatocellular carcinoma.
Lenvatinib Shows Noninferior Survival Outcomes and Improved PFS in HCC
Daneng Li, MD, discusses the results of the REFLECT trial of lenvatinib in hepatocellular carcinoma.
2 Clarke Drive Cranbury, NJ 08512